Cq. Wang et al., Human erythrocyte pyruvate kinase: characterization of the recombinant enzyme and a mutant form (R510Q) causing nonspherocytic hemolytic anemia, BLOOD, 98(10), 2001, pp. 3113-3120
Human erythrocyte pyruvate kinase plays an important role in erythrocyte me
tabolism. Mutation on the gene results in pyruvate kinase deficiency and is
an important cause of hereditary nonspherocytic hemolytic anemia. Because
of difficulties in isolating the mutant enzymes from patients, these mutati
ons have not been fully studied. In this study, a complementary DNA (cDNA)
encoding the human erythrocyte pyruvate kinase was generated. The cDNA was
cloned into several expression vectors, and the protein was expressed and p
urified. The tetrameric protein exhibited properties characteristic of auth
entic human erythrocyte pyruvate kinase, including response to substrate, p
hosphoenolpyruvate, activation by fructose 1,6-bisphosphate, and inhibition
by adenosine triphosphate (ATP). The N-terminal segment of the protein was
highly susceptible to proteolysis, but only 2 of the 4 subunits were cleav
ed and lacked 47 N-terminal amino acid residues. A mutant protein, R510Q, w
hich is the most frequently occurring mutation among Northern European popu
lation, was also generated and purified. The mutant protein retained its bi
nding capacity to and could be activated by fructose 1,6-bisphosphate and s
howed similar kinetics toward phosphoenolpyruvate and adenosine diphosphate
as for the wildtype enzyme. Conversely, the mutant protein has a dramatica
lly decreased stability toward heat and is more susceptible to ATP inhibiti
on. The enzyme instability decreases the enzyme level in the cell, accounti
ng for the clinically observed "pyruvate kinase deficiency" of patients who
are homozygous for this mutation. This study provides the first detailed f
unctional characterization of human erythrocyte pyruvate kinase. These find
ings will allow the establishment of a line correlation between molecular a
bnormalities and the clinical expression of the disease. (C) 2001 by The Am
erican Society of Hematology.